42,021 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Watts Gwilliam & Co. LLC

Watts Gwilliam & Co. LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 42,021 shares of the medical device company’s stock, valued at approximately $3,334,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Whale Capital LLP boosted its position in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after acquiring an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC boosted its stake in DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after buying an additional 11,075 shares in the last quarter. Brooktree Capital Management bought a new position in shares of DexCom in the third quarter worth about $683,000. National Pension Service increased its position in DexCom by 4.1% during the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. bought a new position in DexCom in the 3rd quarter valued at approximately $650,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.30% of the stock is owned by company insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $80.09 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm’s fifty day simple moving average is $76.78 and its 200 day simple moving average is $79.52. The stock has a market cap of $31.28 billion, a P/E ratio of 47.96, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DXCM. Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company increased their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Oppenheimer reduced their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Sanford C. Bernstein upped their price objective on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.